{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:54:28Z","timestamp":1791262468361,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008385","name":"Cystic Fibrosis Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008385","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jcf.2025.01.015","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T07:40:59Z","timestamp":1738827659000},"page":"542-547","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Personalized therapy with CFTR modulators: Response of p.Ile148Asn variant"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8771-4820","authenticated-orcid":false,"given":"Cl\u00e1udia S","family":"Rodrigues","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3713-7089","authenticated-orcid":false,"given":"Violeta","family":"Railean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia S","family":"Ramalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5467-1710","authenticated-orcid":false,"given":"Carlos M","family":"Farinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Pankonien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0828-8630","authenticated-orcid":false,"given":"Margarida D","family":"Amaral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2025.01.015_bib0001","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jcf.2022.01.009","article-title":"Worldwide rates of diagnosis and effective treatment for cystic fibrosis","volume":"21","author":"Guo","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.01.015_bib0002","unstructured":"Patient Registry 2022 | ECFS n.d. https:\/\/www.ecfs.eu\/projects\/ecfs-patient-registry\/annual-reports (accessed July 1, 2024)."},{"key":"10.1016\/j.jcf.2025.01.015_bib0003","first-page":"1066","article-title":"Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA","volume":"245","author":"Riordan","year":"1989","journal-title":"Science (1979)"},{"key":"10.1016\/j.jcf.2025.01.015_bib0004","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1152\/physrev.1999.79.1.S23","article-title":"Structure and function of the CFTR chloride channel","volume":"79","author":"Sheppard","year":"1999","journal-title":"Physiol Rev"},{"key":"10.1016\/j.jcf.2025.01.015_bib0005","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1365-2796.2006.01744.x","article-title":"Evidence for airway surface dehydration as the initiating event in CF airway disease","volume":"261","author":"Boucher","year":"2007","journal-title":"J Intern Med"},{"key":"10.1016\/j.jcf.2025.01.015_bib0006","doi-asserted-by":"crossref","first-page":"921","DOI":"10.2215\/CJN.00750209","article-title":"Renal involvement in cystic fibrosis: diseases spectrum and clinical relevance","volume":"4","author":"Yahiaoui","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"Suppl 2","key":"10.1016\/j.jcf.2025.01.015_bib0007","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/j.jcf.2017.06.011","article-title":"Pancreatic insufficiency in Cystic Fibrosis","volume":"16","author":"Singh","year":"2017","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.01.015_bib0008","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jhep.2021.09.042","article-title":"Cystic fibrosis-related liver disease: clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies","volume":"76","author":"Dana","year":"2022","journal-title":"J Hepatol"},{"issue":"Suppl 2","key":"10.1016\/j.jcf.2025.01.015_bib0009","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1016\/j.jcf.2019.08.010","article-title":"Growth failure and treatment in cystic fibrosis","volume":"18","author":"Le","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.01.015_bib0010","doi-asserted-by":"crossref","DOI":"10.4172\/2472-1018.1000e109","article-title":"Is diabetes related to cystic fibrosis?","volume":"03","author":"Gupta","year":"2017","journal-title":"Lung Dis Treat"},{"key":"10.1016\/j.jcf.2025.01.015_bib0011","unstructured":"CFTR2. CFTR2 database n.d. http:\/\/www.cftr2.org\/. (accessed June 24, 2024)."},{"key":"10.1016\/j.jcf.2025.01.015_bib0012","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S2213-2600(16)00023-0","article-title":"Progress in therapies for cystic fibrosis","volume":"4","author":"De Boeck","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2025.01.015_bib0013","unstructured":"Cystic Fibrosis mutation Database n.d. http:\/\/www.genet.sickkids.on.ca\/. (accessed January 16, 2023)."},{"key":"10.1016\/j.jcf.2025.01.015_bib0014","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/ijms23010024","article-title":"Rare trafficking CFTR mutations involve distinct cellular retention machineries and require different rescuing strategies","volume":"23","author":"Ramalho","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcf.2025.01.015_bib0015","unstructured":"Patient Registry | Cystic Fibrosis Foundation n.d. https:\/\/www.cff.org\/medical-professionals\/patient-registry (accessed July 18, 2024)."},{"key":"10.1016\/j.jcf.2025.01.015_bib0016","doi-asserted-by":"crossref","first-page":"18825","DOI":"10.1073\/pnas.0904709106","article-title":"Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770","volume":"106","author":"Van Goor","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jcf.2025.01.015_bib0017","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1056\/NEJMoa0909825","article-title":"Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation","volume":"363","author":"Accurso","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2025.01.015_bib0018","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jcf.2013.06.008","article-title":"Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function","volume":"13","author":"Van Goor","year":"2014","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.01.015_bib0019","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445-Tezacaftor-Ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2025.01.015_bib0020","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic fibrosis with a single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2025.01.015_bib0021","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nrg3849","article-title":"Cystic fibrosis genetics: from molecular understanding to clinical application","volume":"16","author":"Cutting","year":"2015","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.jcf.2025.01.015_bib0022","unstructured":"Vertex Announces FDA Approvals of TRIKAFTA\u00ae (elexacaftor\/tezacaftor\/ivacaftor and ivacaftor), SYMDEKO\u00ae (tezacaftor\/ivacaftor and ivacaftor) and KALYDECO\u00ae (ivacaftor) for use in people with CF with certain rare mutations | Vertex Pharmaceuticals n.d. https:\/\/investors.vrtx.com\/news-releases\/news-release-details\/vertex-announces-fda-approvals-trikaftar (accessed August 2, 2024)."},{"key":"10.1016\/j.jcf.2025.01.015_bib0023","unstructured":"Vertex Announces U.S. FDA approval for TRIKAFTA (elexacaftor\/tezacaftor\/ivacaftor and ivacaftor) to include additional Non-F508del TRIKAFTA-responsive variants | Vertex Pharmaceuticals n.d. https:\/\/investors.vrtx.com\/news-releases\/news-release-details\/vertex-announces-us-fda-approval-trikafta (accessed January 7, 2025)."},{"key":"10.1016\/j.jcf.2025.01.015_bib0024","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.86581","article-title":"Analysis of cystic fibrosis\u2013associated P67L CFTR illustrates barriers to personalized therapeutics for orphan diseases","volume":"1","author":"Sabusap","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.jcf.2025.01.015_bib0025","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2023.1155705","article-title":"Personalized medicine: function of CFTR variant p.Arg334Trp is rescued by currently available CFTR modulators","volume":"10","author":"Railean","year":"2023","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.jcf.2025.01.015_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2020.165905","article-title":"Organoids as a personalized medicine tool for ultra-rare mutations in cystic fibrosis: the case of S955P and 1717-2A>G","volume":"1866","author":"Silva","year":"2020","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.jcf.2025.01.015_bib0027","doi-asserted-by":"crossref","first-page":"14539","DOI":"10.3390\/ijms241914539","article-title":"CFTR function restoration upon Elexacaftor\/Tezacaftor\/ivacaftor treatment in patient-derived intestinal organoids with rare CFTR genotypes","volume":"24","author":"Lefferts","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcf.2025.01.015_bib0028","doi-asserted-by":"crossref","first-page":"344ra84","DOI":"10.1126\/scitranslmed.aad8278","article-title":"Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis","volume":"8","author":"Dekkers","year":"2016","journal-title":"Sci Transl Med"},{"issue":"24","key":"10.1016\/j.jcf.2025.01.015_bib0029","first-page":"00041","article-title":"Efficacy of elexacaftor-tezacaftor-ivacaftor in portuguese adolescents and adults with cystic fibrosis carrying non-F508del variants","volume":"S2531-0437","author":"Pinto","year":"2024","journal-title":"Pulmonology"},{"key":"10.1016\/j.jcf.2025.01.015_bib0030","article-title":"Protocol for application, standardization and validation of the forskolin-induced swelling assay in cystic fibrosis Human colon organoids","volume":"1","author":"Vonk","year":"2020","journal-title":"STAR Protoc"},{"key":"10.1016\/j.jcf.2025.01.015_bib0031","doi-asserted-by":"crossref","first-page":"5686","DOI":"10.1093\/bioinformatics\/btaa1073","article-title":"An open-source high-content analysis workflow for CFTR function measurements using the forskolin-induced swelling assay","volume":"36","author":"Hagemeijer","year":"2021","journal-title":"Bioinformatics"},{"key":"10.1016\/j.jcf.2025.01.015_bib0032","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jcf.2018.07.001","article-title":"R560S: a class II CFTR mutation that is not rescued by current modulators","volume":"18","author":"Awatade","year":"2019","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1016\/j.jcf.2025.01.015_bib0033","doi-asserted-by":"crossref","first-page":"4495","DOI":"10.1007\/s00018-018-2896-7","article-title":"Proteomic interaction profiling reveals KIFC1 as a factor involved in early targeting of F508del-CFTR to degradation","volume":"75","author":"Canato","year":"2018","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.jcf.2025.01.015_bib0034","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1113\/jphysiol.2005.096669","article-title":"Failure of cAMP agonists to activate rescued \u0394F508 CFTR in CFBE41o\u2013 airway epithelial monolayers","volume":"569","author":"Bebok","year":"2005","journal-title":"J Physiol"},{"key":"10.1016\/j.jcf.2025.01.015_bib0035","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.celrep.2019.01.068","article-title":"Rectal organoids enable personalized treatment of cystic fibrosis","volume":"26","author":"Berkers","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.jcf.2025.01.015_bib0036","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1053\/j.gastro.2004.07.006","article-title":"CFTR Cl\u2212 channel function in native human colon correlates with the genotype and phenotype in cystic fibrosis","volume":"127","author":"Hirtz","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcf.2025.01.015_bib0037","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1002\/ppul.23774","article-title":"A new insight into CFTR allele frequency in Brazil through next generation sequencing","volume":"52","author":"Nunes","year":"2017","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2025.01.015_bib0038","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.921680","article-title":"Pharmacological responses of the G542X-CFTR to CFTR modulators","volume":"9","author":"Fang","year":"2022","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.jcf.2025.01.015_bib0039","article-title":"In vitro modulator responsiveness of 655 CFTR variants found in people with cystic fibrosis","volume":"0","author":"Bihler","year":"2024","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1016\/j.jcf.2025.01.015_bib0040","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s13023-022-02350-5","article-title":"The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis","volume":"17","author":"Costa","year":"2022","journal-title":"Orphanet J Rare Dis"}],"updated-by":[{"DOI":"10.1016\/j.jcf.2026.09.015","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000}}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325000487?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325000487?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T22:08:55Z","timestamp":1762553335000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199325000487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1569199325000487"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2025.01.015","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Personalized therapy with CFTR modulators: Response of p.Ile148Asn variant","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2025.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}